Private Consultation
by Appointment Only
We provide medical advice and consultation tailored to each individual.
Dr. Kubo is here to support anyone living with Parkinson's disease.
Even if you live far away and cannot attend regular appointments,
this is the perfect environment for those who want to consult at their own pace.
Consultation Hours:
| Saturdays, 9:00 AM – 5:00 PM |
Address:
| 4-27-10 Tanashi-cho, Nishi-Tokyo City, Tokyo 188-0011 2-minute walk from Tanashi Station (Seibu Shinjuku Line) |
Target Conditions:
| Parkinson's disease REM sleep behavior disorder Olfactory dysfunction (impaired sense of smell) Dementia with Lewy bodies Atypical parkinsonism/Parkinsonian syndrome |
This clinic specializes exclusively in consultation. We do not provide routine medical services such as prescriptions, diagnostic testing, or the preparation of medical documents.
Notice
Please note that our clinic will be closed on the afternoon of Saturday, October 17, 2026. We apologize for any inconvenience and appreciate your understanding.
Talking helps us face things together.
Take your time, as you would over a chat in a café.
Tell us about your symptoms and how you feel.
Parkinson’s affects everyone differently. Understanding how it affects you is an important step toward finding insights that can help with daily life and treatment.
At our clinic, we respect your doctor’s treatment plan and offer a space for constructive conversations about how to face your worries and concerns.
Alongside the care you receive from your doctor, we aim to be another partner by your side, helping you feel more at ease in everyday life.
We have created a comfortable, spacious setting where you can relax and talk.
About Dr. Kubo
Because I want you to live happily, as yourself.
Since graduating from medical school in 1992, I have devoted all the passion of my medical career to the care and research of Parkinson's disease.
Over the past few decades, treatments, centered on medication, have advanced tremendously. Yet what should matter most, the happiness of each patient, has not always grown along with them. That gap has long weighed on me.
This consultation clinic is where that feeling has led me. My goal is to support you, as you live with Parkinson's disease, so that you can spend each day happily and in a way that is true to who you are.
Some of you may wonder, "Is it all right to ask about something so small?" or "My concerns seem a little different from what this clinic is for." Please rest assured. If it relates to Parkinson's disease, I will gladly listen to whatever is on your mind.
Please feel free to visit us. I look forward to meeting you.
Shin-ichiro Kubo, M.D.
Dr. Kubo's Background
M.D., Tokyo Medical University
Department of Neurology, Juntendo University School of Medicine
Ph.D. (Medical Science), Graduate School of Tokyo Medical University
Departments of Neurology and Physiology, UCSF School of Medicine
Associate Professor, Department of Neurology, Juntendo University School of Medicine
ECFMG certified; passed the United States Medical Licensing Examination (USMLE Steps 1–3).
Medical Director, Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company
Director, Parkinson’s Disease Center, Eisei Hospital & Clinic
Founded the Shin-ichiro Kubo, M.D., Ph.D.
Parkinson’s Disease Consultation
Board Certifications and Qualifications
- Board-Certified Neurologist, Japanese Society of Neurology
Original Reports
- Kubo S, Tsukahara T, Takemitsu M, Yoon KB, Utsumi H, Nonaka I, Arahata K: Presence of emerinopathy in cases of rigid spine syndrome. Neuromuscul Disord 8:502-507, 1998
- Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, Asakawa S, Minoshima S, Yamamura Y, Shimizu N, Mizuno Y: Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 45:668-672, 1999
- Kubo S, Hattori T, Takanashi M, Mori H, Mizutani Y, Suda K, Hattori N, Mizuno Y: A 57-year-old woman with progressive disturbance of gait and mental deterioration. No To Shinkei 52:1035-1044, 2000
- Zhang J, Hattori N, Leroy E, Morris HR, Kubo S, Kobayashi T, Wood NW, Polymeropoulos MH, Mizuno Y: Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat. Disord 6:195-197, 2000
- Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-305, 2000
- Kubo S, Kitami T, Noda S, Shimura H, Uchiyama Y, Asakawa S, Minoshima S, Shimizu N, Mizuno Y, Hattori N: Parkin is associated with cellular vesicles. J Neurochem 78:42-54, 2001
- Hyun DH, Lee M, Hattori N, Kubo S, Mizuno Y, Halliwell B, Jenner P: Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 277:28572-28577, 2002
- Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH: Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24:6715-6723, 2004
- Fukae J, Takanashi M, Kubo S, Nishioka K, Nakabeppu Y, Mori H, Mizuno Y, Hattori N: Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders. Acta Neuropathol (Berl) 109:256-262, 2005
- Fukae J, Kubo S, Hattori N, Komatsu K, Kato M, Aoki M, Mizuno Y: Hoarseness due to bilateral vocal cord paralysis as an initial manifestation of familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 6:122-124, 2005
- Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL: A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 280:31664-31672, 2005
- Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, Hatano Y, Wang M, Imamichi Y, Mizoguchi K, Miyajima H, Obata F, Toda T, Farrer MJ, Mizuno Y, Hattori N: Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 21:1102-1108, 2006
- Arai T, Fukae J, Hatano T, Kubo S, Ohtsubo T, Nakabeppu Y, Mori H, Mizuno Y, Hattori N: Up-regulation of hMUTYH, a DNA repair enzyme, in the mitochondria of substantia nigra in Parkinson's disease. Acta Neuropathol 112:139-145, 2006
- Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N: Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16:678-690, 2007
- Kubo S, Iwatake A, Ebihara N, Murakami A, Hattori N: Visual impairment in Parkinson's disease treated with amantadine: Case report and review of the literature. Parkinsonism Relat Disord 14:166-169, 2008
- Funayama M, Li Y, Tsoi TH, Lam CW, Ohi T, Yazawa S, Uyama E, Djaldetti R, Melamed E, Yoshino H, Imamichi Y, Takashima H, Nishioka K, Sato K, Tomiyama H, Kubo S, Mizuno Y, Hattori N: Familial Parkinsonism with digenic parkin and PINK1 mutations. Mov Disord 23:1461-1465, 2008
- Tomiyama H, Mizuta I, Li Y, Funayama M, Yoshino H, Li L, Murata M, Yamamoto M, Kubo S, Mizuno Y, Toda T, Hattori N: LRRK2 P755L variant in sporadic Parkinson's disease. J Hum Genet 53:1012-1015, 2008
- Kamigaichi R, Kubo S, Ishikawa K, Yokoyama K, Ogaki K, Usui C, Hatta K, Arai H, Mochizuki H, Hattori N: Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report. Eur J Neurol 16:e6, 2009
- Tomiyama H, Li Y, Yoshino H, Mizuno Y, Kubo S, Toda T, Hattori N: Mutation analysis for DJ-1 in sporadic and familial parkinsonism: screening strategy in parkinsonism. Neurosci Lett 455:159-161, 2009
- Shiba K, Arai T, Sato S, Kubo S, Ohba Y, Mizuno Y, Hattori N: Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun 383:331-335, 2009
- Hatano T, Kubo S, Shimo Y, Nishioka K, Hattori N: Unmet needs of patients with Parkinson's disease: interview survey of patients and caregivers. J Int Med Res 37:717-726, 2009
- Hatano T, Shimada Y, Kono A, Kubo S, Yokoyama K, Yoritaka A, Nakahara T, Takahashi Y, Hattori N: Atypical Miller Fisher syndrome associated with glutamate receptor antibodies. BMJ Case Rep, 2011
- Kitami M, Kubo S, Nakamura S, Shiozawa S, Isobe H, Furukawa Y: Acute urinary retention in a 23-year-old woman with mild encephalopathy with a reversible splenial lesion: a case report. J Med Case Reports 5:159, 2011
- Usami Y, Hatano T, Imai S, Kubo S, Sato S, Saiki S, Fujioka Y, Ohba Y, Sato F, Funayama M, Eguchi H, Shiba K, Ariga H, Shen J, Hattori N: DJ-1 associates with synaptic membranes. Neurobiol Dis 43:651-662, 2011
- Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H: Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 35:1704-1708, 2011
- Nagayama H, Kubo S, Hatano T, Hamada S, Maeda T, Hasegawa T, Kadowaki T, Terashi H, Yoshioka M, Nomoto N, Kano O, Inoue M, Shimura H, Takahashi T, Uchiyama T, Watanabe H, Kaneko S, Takahashi T, Baba Y; (Young Japanese Expert Group for Parkinson's Disease and Movement Disorders: YJ-EXPANDS): Validity and reliability assessment of a Japanese version of the Snaith-Hamilton pleasure scale. Intern Med 51:865-869, 2012
- Ujiie S, Hatano T, Kubo S, Imai S, Sato S, Uchihara T, Yagishita S, Hasegawa K, Kowa H, Sakai F, Hattori N: LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat Disord 18: 819-823, 2012
- Hatano T, Kubo S, Niijima-Ishii Y, Hattori N, Sugita Y: Levodopa-responsive Parkinsonism following bilateral putaminal hemorrhages. Parkinsonism Relat Disord 19:477-479, 2013
- Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, Hashida H, Kubo S, Suzuki M, Nanri K, Matsumura M, Murakami H, Hattori N; Tokyo Parkinson's Disease Study Group: Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Intern Med 52:325-332, 2013
- Oji Y, Hatano T, Kubo S, Mori A, Nakazato T, Inui A, Hattori N: Cerebellar ataxia and the “hot cross bun” sign in association with human immunodeficiency virus infection. Neurology and Clinical Neuroscience 1:127, 2013
- Nakayama S, Hatano T, Kubo S, Mori A, Hattori N, Yamada Y, Ogasawara M, Tamura N, Takasaki Y: Leukoencephalopathy associated with low-dose oral methotrexate. Neurology and Clinical Neuroscience 1:128-129, 2013
- Mori A, Hira K, Hatano T, Okuma Y, Kubo S, Hirano K, Ohno K, Noda K, Suzuki H, Ohsawa I, Hattori N: Bilateral facial nerve palsy due to otitis media associated with myeloperoxidase-antineutrophil cytoplasmic antibody. Am J Med Sci 346:240-243, 2013
- Ishikawa KI, Motoi Y, Mizuno Y, Kubo S, Hattori N: Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study. Psychogeriatrics 14:93-100, 2014
- Kano O, Yoshioka M, Nagayama H, Hamada S, Maeda T, Hasegawa T, Kadowaki T, Sengoku R, Terashi H, Hatano T, Nomoto N, Inoue M, Shimura H, Takahashi T, Uchiyama T, Watanabe H, Kaneko S, Takahashi T, Baba Y, Kubo S; The Young Japanese Expert Group for Parkinson's Disease and Movement Disorders: YJ-EXPANDS: Rhinorrhea in Parkinson's disease: A consecutive multicenter study in Japan. J Neurol Sci. 343:88-90, 2014
- Hatano T, Funayama M, Kubo S, Mata IF, Oji Y, Mori A, Zabetian CP, Waldherr SM, Yoshino H, Oyama G, Shimo Y, Fujimoto KI, Oshima H, Kunii Y, Yabe H, Mizuno Y, Hattori N: Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. Neurobiol Aging. 35:2656.e17-23, 2014.
- Nomoto M, Kubo S, Nagai M, Yamada T, Tamaoka A, Tsuboi Y, Hattori N: A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. Clin Neuropharmacol. 38:241-247, 2015
- Kubo S, Hamada S, Maeda T, Uchiyama T, Hashimoto M, Nomoto N, Kano O, Takahashi T, Terashi H, Takahashi T, Hatano T, Hasegawa T, Baba Y, Sengoku R, Watanabe H, Kadowaki T, Inoue M, Kaneko S, Shimura H, Nagayama H; The Young Japanese Expert Group for Parkinson’s Disease and Movement Disorders: YJ-EXPANDS: A Japanese Multicenter Survey Characterizing Pain in Parkinson's Disease. J Neurol Sci. 365:162-166, 2016
- Nagayama H, Maeda T, Uchiyama T, Hashimoto M, Nomoto N, Kano O, Takahashi T, Terashi H, Hamada S, Hasegawa T, Hatano T, Takahashi T, Baba Y, Sengoku R, Watanabe H, Inoue M, Kadowaki T, Kaneko S, Shimura H, Kubo S; The Young Japanese Expert Group for Parkinson’s Disease and Movement Disorders: YJ-EXPANDS: Anhedonia and its correlation with clinical aspects in Parkinson’s Disease. J Neurol Sci. 372:403-407, 2017
- Mori A, Hatano T, Inoshita T, Shiba-Fukushima K, Koinuma T, Meng H, Kubo SI, Spratt S, Cui C, Yamashita C, Miki Y, Yamamoto K, Hirabayashi T, Murakami M, Takahashi Y, Shindou H, Nonaka T, Hasegawa M, Okuzumi A, Imai Y, Hattori N: Parkinson's disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling. Proc Natl Acad Sci U S A. 116:20689-20699, 2019
- Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu Y, Kim DK, Jung BC, Choi M, Oh KW, Li Y, Nakatani M, Nakazato T, Sekimoto S, Funayama M, Yoshino H, Kubo SI, Nishioka K, Sakai R, Ueyama M, Mochizuki H, Lee HJ, Sardi SP, Halliday GM, Nagai Y, Lee PH, Hattori N, Lee SJ: Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Brain. 142:2845-2859, 2019
- Kubo SI, Nakamura K, Tada Y, Kashio N, Yamashita S: What can we learn from the effect of trihexyphenidyl on motor fluctuations during continuous levodopa-carbidopa intestinal gel infusion (LCIG)? – First documented case. Clin Parkinsonism Relat Disord. 3:100071, 2020
- Kubo SI, Matsubara T, Taguchi T, Sengoku R, Takeuchi A, Saito Y: Parkinson’s disease with a typical clinical course of 17 years overlapped by Creutzfeldt–Jakob disease: An autopsy case report. BMC Neurol. 21:480, 2021
- Matsui H, Ito S, Matsui H, Ito J, Gabdulkhaev R, Hirose M, Yamanaka T, Koyama A, Kato T, Tanaka M, Uemura N, Matsui N, Hirokawa S, Yoshihama M, Shimozawa A, Kubo SI, Iwasaki K, Hasegawa M, Takahashi R, Hirai K, Kakita A, Onodera O: Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease. Proc Natl Acad Sci U S A. 120(23):e2214652120, 2023
- Kubo SI, Ito M, Matsuba K, Shimono T: The effects of lactulose on constipation in patients with Parkinson's disease: An exploratory pilot study. eNeurologicalSci. 35:100503, 2024
- Okusa S, Saegusa H, Miyakawa K, Tsutsumi Y, Ishida S, Nishikata K, Nukariya T, Tezuka T, Nihei Y, Kitagawa Y, Kubo SI, Suzuki N, Nakahara J, Seki M: Satisfaction, effectiveness, and usability of telerehabilitation for Parkinson's disease patients. J Rehabil Med. 57:jrm39819, 2025
- Hiroki Saegusa, Shohei Okusa, Tomonori Nukariya, Toshiki Tezuka, Yoshihiro Nihei, Yasuhiro Kitagawa, Shin-ichiro Kubo, Yasuo Terayama, Norihiro Suzuki, Jin Nakahara, Morinobu Seki: Association Between a 1-Year Group-Based Telerehabilitation Program and the Quality of Life of People With Parkinson's Disease: An Observational Study. Arch Phys Med Rehabil. 8:S0003-9993(26)00073-0, 2026
Reviews
- Hattori N, Shimura H, Kubo S, Wang M, Shimizu N, Tanaka K, Mizuno Y: Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease. J Neural Transm Suppl 60:101-116, 2000
- Hattori N, Shimura H, Kubo S, Kitada T, Wang M, Asakawa S, Minashima S, Shimizu N, Suzuki T, Tanaka K, Mizuno Y: Autosomal recessive juvenile parkinsonism: a key to understanding nigral degeneration in sporadic Parkinson's disease. Neuropathology 20 Suppl:S85-90, 2000
- Hattori N, Shimura H, Kubo S, Suzuki T, Tanaka K, Mizuno Y: Autosomal recessive juvenile parkinsonism: its pathogenesis is involved in the ubiquitin-proteasome pathway. Rinsho Shinkeigaku 40:1293-1296, 2000
- Mizuno Y, Hattori N, Kitada T, Matsumine H, Mori H, Shimura H, Kubo S, Kobayashi H, Asakawa S, Minoshima S, Shimizu N: Familial Parkinson's disease. Alpha-synuclein and parkin. Adv Neurol 86:13-21, 2001
- Kubo S, Hattori N, Mizuno Y: Recessive Parkinson’s disease. Mov Disord 21:885-893, 2006
- Hattori N, Machida Y, Sato S, Noda K, Iijima-Kitami M, Kubo S, Mizuno Y: Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins. J Neural Transm Suppl 70:205-208, 2006
- Hattori N, Kubo S: The pathogenesis of Parkinson's disease: a hint from insights of familial Parkinson's disease. Rinsho Shinkeigaku 47:774-778, 2007
- Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, Tomiyama H, Funayama M, Machida Y, Mochizuki H: Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 363:2215-2227, 2008
- Hatano T, Kubo S, Sato S, Hattori N: Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem 111:1075-1093, 2009
- Hattori N, Wang M, Taka H, Fujimura T, Yoritaka A, Kubo S, Mochizuki H: Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 1:S35-S38, 2009
- Kubo S, Hattori N: Neurodegenerative disease: Can synucleinopathy and tauopathy be identified during life? Nat Rev Neurol 9:426-427, 2013
- Kubo S, Hatano T, Takanashi M, Hattori N: Can parkin be a target for future treatment of Parkinson's disease? Expert Opin Ther Targets 17:1133-1144, 2013
- Kubo S, Hatano T, Oyama G, Hattori N: Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease: JAPAN. Neurol Clin Pract 3:477-478, 2013
- Hatano T, Kubo S, Hattori N, Mizuno Y: Movement disorders in neoplastic brain disease. In: Movement Disorders in Neurologic and Systemic Disease. Eds: Werner Poewe and Joseph Jankovic, Cambridge University Press, 279-292, 2014
- Kubo S, Hatano T, Hattori N: Lipid rafts involvement in the pathogenesis of Parkinson’s disease. Front Biosci 20:263-279, 2015
- Kubo S: Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids. Expert Opin Ther Targets 20:1301-1310, 2016
Articles in Japanese
- 久保紳一郎、塚原俊文、荒畑喜一。エメリー・ドレイフス型筋ジストロフィー。日本臨牀 55(12):3186-3189, 1997
- 服部信孝，志村秀樹，久保紳一郎，北田徹，浅川修一，清水信義，水野美邦．家族性パーキンソニズムの原因遺伝子．Prog Med 19:1403-1408, 1999
- 久保紳一郎，志村秀樹，服部信孝，水野美邦．常染色体劣性若年性パーキンソニズム．Kinesis 4:12-15, 1999
- 服部信孝，志村秀樹，久保紳一郎，水野美邦：若年性パーキンソニズム．神経研究の進歩。 44:555-566, 2000
- 久保紳一郎，志村秀樹，服部信孝，水野美邦：パーキンソン病の分子医学．現代医療 32:115-122, 2000
- Hattori N, Shimura H, Kubo S, Suzuki T, Tanaka K, Mizuno Y: Autosomal recessive juvenile parkinsonism: its pathogenesis is involved in the ubiquitin-proteasome pathway. Rinsho Shinkeigaku 40:1293-1296, 2000
- 久保紳一郎，服部信孝，水野美邦：Parkinson病研究の最前線．最新医学 56:38-44, 2001
- 服部信孝，久保紳一郎，小林洋和，北見聡章，佐藤健一，水野美邦：家族性パーキンソン病．内科 87:660-667, 2001
- 服部信孝，久保紳一郎，北見聡章，王梅，佐藤健一，水野美邦：parkin遺伝子とその異常．CLINICAL NEUROSCIENCE 19:656-659, 2001
- 久保紳一郎，服部信孝，水野美邦：パーキンソン病の研究の方向と進歩．Geriatric Medicine 40:55-61, 2002
- 久保紳一郎，服部信孝：知っておきたい200 words―現代医学理解のために：パーキン．医学のあゆみ 200:1226-1227, 2002
- 久保紳一郎，服部信孝：目でみるバイオサイエンス：Parkin遺伝子．内科 89:546-550, 2002
- 久保紳一郎, 服部信孝：パーキンソン病研究の最前線．実験医学 23: 1955-1962, 2005
- 久保紳一郎：パーキンソン病-最近の進歩- 遺伝性パーキンソン病の病態から LRRK2の機能-タンパク質凝集の上流に位置するのか？- 最新医学 62: 1660-1664, 2007
- 久保紳一郎： LRRK2と神経変性疾患。内科 99: 875-878, 2007
- Hattori N, Kubo S: The pathogenesis of Parkinson's disease: a hint from insights of familial Parkinson's disease. Rinsho Shinkeigaku 47:774-778, 2007
- 久保紳一郎：パーキンソン病治療-New Standards電気けいれん療法．Clinical Neuroscience 29:588-599, 2011
- 久保紳一郎：パーキンソン症候群。内科109:972-975, 2012
- 久保紳一郎、波田野琢、服部信孝：よく使う日常治療薬の正しい使い方Parkinson病薬物治療の実際。レジデントノート15:2313-2318, 2013
- 波田野琢、久保紳一郎、服部信孝：Dopamine dysregulation syndrome．Clinical Neuroscience 31:1305-1307, 2013
- 久保紳一郎：3番染色体に連鎖する遺伝性パーキンソン病（PARK8）。別冊日本臨床 新領域別症候群シリーズ27:86-87, 2014
- 久保紳一郎：嗅覚障害とパーキンソン病。日本医師会雑誌142:2657, 2014
- 久保紳一郎、波田野琢、服部信孝：早期Parkinson病。内科113:1391-1394, 2014
Textbooks in Japanese
- 久保紳一郎：常染色体優性パーキンソン病．パーキンソン病ハンドブック，水野美邦、中外医学社，東京，310-316，2001
- 久保紳一郎：塩酸アマンタジン、抗コリン薬の効果と安全性に関するエビデンス。 最新医学・別冊 新しい診断と治療のABC 39、水野美邦、最新医学社、大阪、122-133, 2006
- 久保紳一郎：Q67. 1日300mg以上の塩酸アマンタジンがジスキネジアを抑制するといわれますが、同じ薬物が維持量の違いによってパーキンソニズムに効いたり、ジスキネジアに効いたりする機序は何なのでしょうか？．パーキンソン病診療Q&A110，水野美邦、中外医学社，東京，205-209，2009
- 久保紳一郎：Q2.パーキンソン病の原因は？．パーキンソン病Q&A，服部信孝、日本医事新報社，東京，5-8，2009
- 久保紳一郎：睡眠障害、視力および視野障害、急性横断性脊髄障害、脳脊髄液の検査．神経内科ハンドブック第4版，水野美邦、医学書院，東京，177-186, 257-267, 375-380, 382-393，2010
- 久保紳一郎：ハンチントン病、前頭側頭葉変性症、アルツハイマー病、SCA17、MJD/SCA3、SCA2．よくわかるパーキンソン病のすべて，水野美邦、近藤智善、永井書店，東京，297-311，2011
- 久保紳一郎、波田野琢、服部信孝：常染色体劣性パーキンソン病．アクチュアル脳・神経疾患の臨床，辻省次、高橋良輔、中山書店，東京，400-406，2013
- 久保紳一郎：睡眠障害、視力および視野障害、急性横断性脊髄障害、脳脊髄液の検査．神経内科ハンドブック第5版，水野美邦、医学書院，東京，178-187, 258-270, 398-402, 404-416，2016
Clinic Photos
Cancelling or Rescheduling Your Appointment
To cancel an appointment, please submit the dedicated form below. Except in unavoidable circumstances, we ask that you notify us as far in advance as possible. Please note that we may decline future bookings from patients who cancel frequently.
If you wish to reschedule your appointment, please choose a date and time when you can attend.
Frequently Asked Questions
Here are answers to the questions we are asked most often. Click a question to see the answer.
I'm having trouble booking or canceling an appointment online.
We apologize for the inconvenience. Please contact us using our dedicated form, and a member of our system support staff will assist you.
Can I consult about conditions other than Parkinson's disease?
Yes. We also offer consultations for the other conditions listed under “Target Conditions”.
Is there parking available?
We do not have a parking lot. If you are coming by car, please use one of the nearby coin-operated parking lots. If you are coming by train, we are a 2-minute walk from the North Exit of Tanashi Station on the Seibu Shinjuku Line.
Will I run into other patients in the waiting room?
All visits are by appointment only. To protect your privacy, we do not show the next patient in until the previous patient has left.
What payment methods do you accept?
We accept cash only. Credit cards, e-money, and other cashless payment methods cannot be used.
Do I need a referral letter?
No, you can be seen without a referral letter. If you have one, please bring it with you on the day of your visit.
Can I get prescriptions or vaccinations?
As a clinic dedicated to medical consultations, we do not prescribe medication or administer vaccinations.
Can I visit in a wheelchair?
Yes. Inside the building, a ramp leads from the entrance. There is a step between the street and the black entrance door, but our staff will be happy to help—just let us know.
How many family members may accompany the patient?
As a rule, we ask that no more than one person accompany the patient. If a second companion is necessary, up to three people in total, including the patient, may enter.
Is there anything I should bring to my appointment?
If you have a medication record book (okusuri techo), please bring it with you on the day of your visit.
Location
Address:
4-27-10 Tanashi-cho, Nishi-Tokyo City, Tokyo 188-0011
2-minute walk from Tanashi Station (Seibu Shinjuku Line)
Five-part series
Understanding Parkinson's Disease
Part 1
Hand tremors and difficulty moving. How is Parkinson's disease diagnosed?
From changes in movement to the role of examinations and tests, learn how Parkinson's disease is diagnosed.
Read Part 1